GetTopicDetailResponse(id=ac6f12398984, topicName=復發(fā)或難治性MCL, introduction=, content=伊布替尼 維奈托克 復發(fā)或難治性MCL, image=null, comments=0, allHits=349, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Feb 06 11:34:26 CST 2025, time=2025-02-06, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=501187, tagList=[TagDto(tagId=501187, tagName=復發(fā)或難治性MCL)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2250715, encodeId=8a452250e15fd, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a> <a href='/topic/show?id=1115e90262d' target=_blank style='color:#2F92EE;'>#維奈托克#</a> <a href='/topic/show?id=ac6f12398984' target=_blank style='color:#2F92EE;'>#復發(fā)或難治性MCL#</a>, objectTitle=Lancet Oncol | 突破性進展：伊布替尼-維奈托克為 MCL 患者提供新的治療選擇, objectType=article, longId=862116, objectId=396c862116d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250205/1738757532316_6145188.jpg, objectUrl=/article/show_article.do?id=396c862116d8, replyNumber=0, likeNumber=38, createdTime=2025-02-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=396c862116d8, moduleTitle=Lancet Oncol | 突破性進展：伊布替尼-維奈托克為 MCL 患者提供新的治療選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=396c862116d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-02-06發(fā)表于陜西省
